Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis by Lee, Chang Youl et al.
The  Korean  Journal  of  Internal  Medicine:  23:116-120,  2008
Clinical significance of insulin-like growth factor-1 receptor 
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Background/Aims:  The  insulin-like  growth  factor  (IGF)  system  has  been  implicated  in  tumor  growth,  invasion,  and 
metastasis.  However,  reports  on  the  IGF-1  receptor  (IGF-1R)  based  on  radioimmunoassays  are  conflicting,  and  its 
prognostic  implications  in  non-small-cell  lung  cancer  (NSCLC)  ar e  s t i l l  c o n t r o v e r s i a l .
Methods: Seventy-one paraffin-embedded tissue sections from stage I NSCLC patients were stained using
  a mouse 
monoclonal  antibody  against  human  IGF-1R.
Results:  The  intensity  and  frequency  of  IGF-1R  expression  on  the  membrane  and  cytoplasm  of  cancer  cells  was 
evaluated  and scored  using  a  semiquantitative  system.  IGF-1R  expression was detected in nine of 71 (12.7%) cases. 
No significant relationship was found between clinical/histopathological parameters and IGF-1R expression. None of the 
patients  whose  tumor  expressed  IGF-1R  had  experienced  distant  metastasis  or  cancer-related  death,  although  the 
difference  did  not  reach  statistical  significance.
Conclusions:  We  conclude  that  IGF-1R  expression  may  not  be  a  major  prognost i c  f a c t o r  f o r  s t a g e  I  N S C L C .
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INTRODUCTION
Non-small-cell  lung  cancer  (NSCLC)  accounts  for  approxi-
mately 75～80% of all lung cancers and is the leading cause of 
cancer-related deaths worldwide
1). However, 20% of stage I and 
30%  of  stage  II  NSCLC  patients  who  are  treated  with  curative 
intent  experience  recurrence  of  their  cancer,  which  is  often 
incurable  at  the  time  of  discovery.  This  statistic  indicates  the 
urgent need to elucidate the carcinogenesis of lung cancer and 
to devise new approaches for its prevention and treatment, such 
as  chemoprevention.
The insulin-like growth factor (IGF) system plays a critical role 
in  the  growth  and  development  of  many  tissues  and  regulates 
overall  growth,  particularly  prenatal  growth.  It  has  also  been 
implicated  in  various  pathophysiological  conditions  and  is 
thought  to  play  a  prominent  role  in  tumorigenesis.  The  insulin- 
like  growth  factor-1  receptor  (IGF-1R)  is  a  glycosylated 
heterotetramer  composed  of  two  extracellular  α-  and  β
-subunits that have intrinsic tyrosine kinase activity, and it shares 
70%  homology  with  the  insulin  receptor.  It  is  encoded  by  the 
IGF-1R  gene  located  on  chromosome  15q26
2, 3).  IGF-1R  mainly 
mediates  the  effect  of  IGFs,  which  are  potent  mitogens  that Chang  Youl  Lee,  et  al:  IGF-1R  in  stage  I  NSCLC 117
regulate  cell  proliferation,  differentiation,  and  protection  from 
apoptosis
4).  Clinical  and  epidemiological  data  suggest  that  the 
serum  levels  of  IGF-1  and  IGF-binding  proteins  (IGFBPs)  are 
r e l a t e d  t o  t h e  r i s k  o f  s o l i d  t u m o r s ,  s u c h  a s  b r e a s t ,  p r o s t a t e ,  
endometrial,  ovarian,  and  colon  cancer
5).  In  breast  cancer, 
IGF-1R  expression  and  activation  have  been  linked  to  disease 
progression,  increased  resistance  to  radiotherapy,  and  a  poor 
prognosis
6, 7).
  The  expression  of  a  dominant-negative  truncated 
IGF-1R in colon cancer cells reduced the expression of vascular 
endothelial  growth  factor,  impaired  tumor  progression  in  nude 
mice,  and  increased  tumor  cell  apoptosis
8).  More  focused 
studies  of  IGF-1R  expression  in  the  breast  and  prostate  that 
used immunohistochemistry or matched cell lines corresponding 
to normal and tumor tissue revealed that normal epithelium and 
e a r l y - s t a g e  t u m o r s  b o t h  e x p r e s s  a b u n d a n t  I G F - 1 R  a n d  t h a t  i t s  
expression  is  reduced  significantly  in  advanced  metastatic 
cancer
9-13).
Although  several  commercial  anti-IGF-1R  antibodies  are 
available,  no  scoring  system  for  IGF-1R  expression  in 
formalin-fixed,  paraffin-embedded  tissue  has  been  established. 
Here, we report the prognostic implications of IGF-1R expression 
as determined immunohistochemically using archived materials of 
stage  I  NSCLC.  We  evaluated  its  expression  in  cancer  cell 
membranes  and  the  cytoplasm  and  correlated  its  expression 
with  various  clinicopathological  parameters.
MATERIAL AND METHODS
Study  population  and  samples
We  examined  71  tissue  specimens  from  stage  I  NSCLC 
patients who had undergone
  curative surgical removal of primary 
lesions between 1995 and 1998 at Yonsei Medical Center. The 
pathological  evaluation  established  the  histological
  classification 
and  stage  in  all  patients.  None  of  the
  patients  had  either 
radiotherapy  or  chemotherapy  before  or  after
  surgery  until  the 
disease  recurred.  All  clinical  and  pathological
  information  and 
follow-up  data  were  obtained  from  reports  from  our
  registry 
service.  The  study  was  reviewed  and  approved
  by  the 
institution’s  Surveillance  Committee  to  allow  us
  to  obtain 
pertinent  information  from
  the  patients’  files.
Immunohistochemical  staining  for  IGF-1R
Paraffin-embedded,  4-µm-thick  tissue  sections  were  stained 
with  mouse  monoclonal  antibody  against  human  IGF-1R 
(BioSource International, Camarillo, CA, USA). The sections
  were 
deparaffinized  in  a  xylene  bath,  rehydrated
  using  a  graded 
alcohol series, and retrieved in 10 mM sodium citrate buffer via 
microwave  heating  for  15  min  at  95℃.  The  sections  were  then 
t r e a t e d  w i t h  0 . 3 %  h y d r o g e n  p e r o x i d a s e  f o r  1 0  m i n  t o
  block 
endogenous peroxidase activity. Subsequently, the sections were 
incubated  with  the  primary  anti-IGF-1R  antibody  (1:50)  for  30 
min  at  room  temperature  and  processed  using  standard 
avidin-biotin
  immunohistochemical  techniques  according  to  the 
manufacturer’s
  recommendations  (Vector  Laboratories,  Burlin-
game, CA, USA). Diaminobenzidine (DAB)
  was used as a chro-
mogen,  and  commercial  hematoxylin  was  used
  for  counter-
staining.  Each  time,  placenta  and  breast  cancer  tissues  were 
stained to serve as positive controls. Adjacent normal-appearing
 
bronchial  epithelium  within  each  tissue  section  served  as  an
 
internal reference. The intensity of IGF-1R immunostaining of the 
membrane  and  cytoplasm  of  the  invasive  cancer  components 
was  evaluated.  Cell  membrane  and  cytoplasm  staining  were 
scored  on  a  scale  of  0,  1+,  2+,  and  3+,  where  scores  of  1+ 
and above were  classified as  positive.  All  slides  were evaluated
 
and scored independently by two pathologists who were blind to 
the  subjects’  clinical  information.
Statistical  analysis
In  the  univariate  analysis,  independent  sample  t-tests  and 
Fisher’s  exact  tests
  were  used  for  continuous  and  categorical 
variables,  respectively.
  The  Kaplan-Meier  estimator  was  used  to 
compute survival probability
  as a function of time. The log-rank 
t e s t  w a s  u s e d  t o  c o m p a r e
  survival  time  between  groups.  All 
statistical  tests  were  two-sided.
  p<0.05  was  considered 
significant.
RESULTS
Patient  demographic  characteristics
The NSCLC cases included 51 (71.8%) males and 20 (28.2%) 
females with a median age of 61.8 (31-83)
  years, which is similar 
to the distribution in the large
  database of patients with stage I 
NSCLC from our institution
  (data not shown). Thirty-five (49.3%) 
patients were diagnosed with adenocarcinoma, 33 (46.5%) with 
squamous  cell  carcinoma,  and  three  (4.2%)  with  other 
histological subtypes. Fifty-eight (81.7%) patients had a history of 
smoking.  The  general  clinical  characteristics
  o f  t h e  p a t i e n t s  a r e  
shown  in  Table  1.
IGF-1R  immunohistochemistry
IGF-1R expression was granular, heterogeneous, and discrete, 
i.e., mainly localized to the cytoplasm of NSCLC cells (Figure 1A 
and  B).  Some  bronchioloalveolar  carcinoma  tissue  showed 
d i s t i n c t  c y t o p l a s m i c  I G F - 1 R  e x p r e s s i o n  ( F i g .  1 C ) .  H o w e v e r ,  t h e  
number  of  NSCLC  tissues  expressing  IGF-1R  was  small.  There 
w e r e  6 2  ( 8 7 . 3 % ) ,  s e v e n  ( 9 . 9 % ) ,  t w o  ( 2 . 8 % ) ,  a n d  z e r o  ( 0 . 0 % )  
NSCLC cases with IGF-1R staining scores of 0, 1+, 2+, and 3+, 
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Total
IGF-1R  expression
p-value
positive  (%) negative  (%)
Gender
Male
Female
Histologic  subtypes
Adenocarcinoma+BAC*
Squamous  cell  carcinoma
Large  cell  carcinoma
Adenocarcinoma  +  Squamous  cell  carcinoma
Grade  of  differentiation
Well  differentiated
Poor  differentiated
Smoking  status
Never  smoker
Former/current  smoker
Distance  metastasis
Cancer  related  death
51
20
35
33
2
1
20
16
13
58
8
3
11.8
15
14.3
11.4
0
0
20
12.5
7.7
13.8
0
0
88.2
85
85.7
886
100
100
80
87.5
92.3
86.2
100
100
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
Total  evaluated 71 12.7 87.3
*Bronchioloalveolar  carcinoma 
Table  1.  Analysis  of  the  patients  with  stage  I  NSCLC  according  to  the  expression  status  of  IGF-1R
positive and were used for the subsequent statistical analysis. In 
the  normal-appearing  adjacent  lung  tissues,  the  cytoplasm  of 
bronchial/bronchiolar  epithelium  showed  uniform,  constant 
IGF-1R expression. The immunohistochemical staining of IGF-1R 
in  breast  cancer  and  placenta  tissues  was  also  stable  and 
r e p r o d u c i b l e  ( d a t a  n o t  s h o w n ) .
Correlation  of  IGF-1R  expression  with  the  clinicopathological 
parameters
IGF-1R  expression  was  positive  in  nine  (12.7%)  cases  and 
negative  in  62  (87.3%).  IGF-1R  expression  was  not  associated 
with  the  clinical  or  pathological  characteristics  tested  in  this 
s t u d y  ( T a b l e  1 ) .  T h e  o v e r a l l  s u r v i v a l  c u r v e s  d i d  n o t  d i f f e r  
significantly  between  the  group  of  patients  with  tumors 
expressing  IGF-1R  and  those  with  negative  IGF-1R  expression 
(Figure 2). None of the patients with positive IGF-1R expression 
experienced distant metastasis or cancer-related death, although 
the  difference  did  not  reach  significance  (Table  1).
DISCUSSION
IGFs are potent mitogens in several types of cancer, including 
NSCLC and small-cell lung cancer
15, 16). Furthermore, IGF-1R can 
upregulate  several  aspects  of  the  malignant  phenotype  and 
metastasis  in  vitro
17).  In  breast  cancer,  IGF-1R  expression  and 
activation  have  been  linked  to  disease  progression,  increased 
resistance  to  radiotherapy,  and  a  poor  prognosis
18, 19).  For  lung 
cancer,  no  data  are  available  on  IGF-1R  expression,  so  we 
f o c u s e d  o n  t h e  e x p r e s s i o n  o f  I G F - 1 R  i n  p a t i e n t s  w i t h  s t a g e  I  
NSCLC  and  its  significance  to  the  clinical  outcome.  We  tested 
the  prognostic  significance  of  IGF-1R  expression  in 
formalin-fixed,  paraffin-embedded  tissues.
We  found  that  IGF-1R  expression  was  downregulated  in  a 
significant fraction of patients with stage I NSCLC. Overall, nine 
o f  7 1  t u m o r s  e x p r e s s e d  I G F - 1 R ,  a n d  i t s  e x p r e s s i o n  w a s  
localized  to  the  membrane  and  cytoplasm,  rather  than  the 
nucleus  of  NSCLC  cells.  Our  data  indicate  that  IGF-1R 
expression  is  not  a  prognostic  factor  in  patients  with  stage  I 
NSCLC.  None  of  the  patients  expressing  IGF-1R  experienced 
distant  metastasis  or  cancer-related  death,  although  the 
difference  was  not  significant.  Our  study  did  not  show  a  better 
survival  with  IGF-1R  expression. Other  studies have shown that 
IGF-1R  expression  was  significantly  associated  with  a  better 
survival  in  breast  cancer  and  highly  malignant  soft  tissue 
sarcoma
20, 21),  a l t h o u g h  o t h e r  s t u d i e s  f o u n d  t h e  o p p o s i t e
22, 23). 
Early  studies  showed  that  functionality  of  the  IGF-1R  was  a 
prerequisite  for  neoplastic  transformation  and  for  survival  of  the 
transformed cell in vitro and in vivo
24). More recent evidence has 
pointed to putative roles for IGF-1R in cell adhesion and cancer 
cell  dedifferentiation
25).  The  significant  association  with  survival 
observed i n t hi s s t udy i s of  par t i cul ar rel evance,  and s houl d be 
confirmed  in  additional  cohorts  of  patients.
In  summary,  in  a  homologous  population  of  71  patients  with 
stage  I  NSCLC,  we  showed  that  IGF-1R  expression  is  neither 
frequent nor a prognostic factor in stage I NSCLC. More compre-
hensive studies of the mechanism of IGF-1R expression in NSCLC 
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Figure  1.  Immunohistochemical  analysis  of  IGF-1R  expression  in  stage  I  NSCLC  tissues.  A.  Poorly  differentiated  adenocarcinoma  with  2+  IGF-1R 
expression  (×400).  B.  Squamous  cell  carcinoma  with  1+  IGF-1R  expression  (×200).  C.  Bronchioloalveolar  carcinoma  with  2+  IGF-1R e x p r e s s i o n  
(×200).  D.  Another  bronchioloalveolar  carcinoma  that  did  not  express  IGF-1R  (×200).
Figure  2.  S u r v i v a l  c u r v e  f o r  p a t i e n t s  w i t h  s t a g e  I  N S C L C  s t r a t i f i e d  b y  
IGF-1R  expression.  There  was  no  significant  difference  between  the 
curves  for  patients  with  and  without  IGF-1R  expression.
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